Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
14.65 ^USD	+3.31%		-0.14%	-9.18%

Mar. 13	Transcript : Deciphera Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:00 AM
Feb. 06	Deciphera Pharmaceuticals' Q4 Net Loss Narrows, Revenue Rises	MT

Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 06, 2024 at 07:00 am EST

Deciphera Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 163.36 million compared to USD 134.04 million a year ago. Net loss was USD 194.94 million compared to USD 178.93 million a year ago.

Basic loss per share from continuing operations was USD 2.29 compared to USD 2.37 a year ago. Diluted loss per share from continuing operations was USD 2.29 compared to USD 2.37 a year ago.

Latest news about Deciphera Pharmaceuticals, Inc.

Transcript : Deciphera Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:00 AM	Mar. 13
Deciphera Pharmaceuticals' Q4 Net Loss Narrows, Revenue Rises	Feb. 06	MT
Transcript : Deciphera Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 06, 2024	Feb. 06
Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q4 Revenue $48.3M, vs. Street Est of $46.8M	Feb. 06	MT
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 06	CI
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 06	CI
North American Morning Briefing : Rate Doubts Keep -2-	Feb. 06	DJ
Deciphera Says Long-Term Data Show 'Similar' Overall Survival Rates for Qinlock, Sunitinib	Jan. 18	MT
Deciphera Pharmaceuticals Partners With Genesis Pharma to Distribute Cancer Drug in 14 European Countries	Jan. 12	MT
GENESIS Pharma and Deciphera Pharmaceuticals, Inc. Announce an Exclusive Distribution Agreement for RIPRETINIB in 14 European Markets in Central and Eastern Europe	Jan. 12	CI
Transcript : Deciphera Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 04:30 PM	Jan. 09
Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	Jan. 08	CI
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18	Jan. 05	CI
North American Morning Briefing : Fed Decision, -2-	Nov. 01	DJ
Deciphera Pharmaceuticals Insider Sold Shares Worth $259,256, According to a Recent SEC Filing	23-10-31	MT
HC Wainwright Adjusts Deciphera Pharmaceuticals' Price Target to $30 From $25, Keeps Buy Rating	23-10-31	MT
JonesTrading Upgrades Deciphera Pharmaceuticals to Buy From Hold, $16 Price Target	23-10-31	MT
North American Morning Briefing : Lower Treasury -2-	23-10-31	DJ
Piper Sandler Upgrades Deciphera Pharmaceuticals to Overweight From Neutral, Raises Price Target to $23 From $18	23-10-30	MT
Deciphera Pharmaceuticals' Q3 Net Loss Widens, Revenue Rises; Says Phase 3 Tumor Drug Trial Met Primary Endpoint	23-10-30	MT
Transcript : Deciphera Pharmaceuticals, Inc., Q3 2023 Earnings Call, Oct 30, 2023	23-10-30
Earnings Flash (DCPH) DECIPHERA PHARMACEUTICALS Posts Q3 Revenue $43.3M	23-10-30	MT
Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-30	CI
Deciphera Pharmaceuticals, Inc. Announces Positive Top-Line Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor	23-10-30	CI
North American Morning Briefing : Stock Futures -2-	23-08-11	DJ

Chart Deciphera Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.

Sector

Biotechnology & Medical Research

Calendar

2024-04-30 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Deciphera Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.65 USD

Average target price

24.2 USD

Spread / Average Target

+65.19%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DECIPHERA PHARMACEUTICALS, INC.	-9.18%	1.2B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs